Genetic knockout or pharmacological blockade of ASK1 reduces renal inflammation and fibrosis in unilateral ureteral obstruction (UUO) [7] and CKD [8], which implies that ASK1 is a potential therapeutic target for the treatment of CKD. This evidence concerns the gene MAP3K5 and chronic kidney disease.